Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Jul 14, 2023

  • Pharmaceuticals
  • Corporate

Chugai Files Patent Infringement Lawsuit against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the U.S.

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Kae Miyata
Head of Corporate Communications Dept.

Chugai Pharmaceutical Co., Ltd. announced today that Chugai, Roche and Genentech have filed a patent infringement lawsuit in the United States District Court for the District of Massachusetts as follows.

  1. Date of Complaint
    July 13, 2023 (local time)
  2. Reasons for the Action
    In response to Biogen MA Inc. (“Biogen”)’s filing of an abbreviated biologics license application (“aBLA”) to the U.S. Food and Drug Administration for approval of a biosimilar to Actemra® (generic name: tocilizumab), Chugai, Roche and Genentech filed a patent infringement lawsuit against Biogen together with its business partner Bio-Thera Solutions, Ltd., who developed biosimilar products subject to Biogen’s aBLA, seeking judgments including infringement of Chugai, Roche, and Genentech’s U.S patents under the framework of Biologics Price Competition and Innovation Act (“BPCIA”). Patents in suit include but not limited to patents related to methods of using tocilizumab in intravenous form, and methods of manufacturing tocilizumab.
  3. Defendants
    1. Name: Biogen MA Inc.
      Address: 225 Binney Street Cambridge, MA 02142 USA
    2. Name: Bio-Thera Solutions, Ltd.
      Address: 11 Kai-Yuan Blvd, Huangpu District, Guangzhou, China
  4. Prospects
    No changes are expected to be made to Chugai’s financial prospects at this point.


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail:
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top